BTX161 - HY-120084
Nur noch %1 verfügbar
Catalog #
HY-120084
Ab
393,00 €
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-120084/BTX161-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | Cancer-Kinase/protease |
| CAS | 2052301-24-1 |
| Storage | -20°C, 3 years; 4°C, 2 years (Powder) |
| MWT | 272.304 |
| Solubility | DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C) |
| Clinical Information | No Development Reported |
| Target | Casein Kinase |
| Application: | Cancer-Kinase/protease |
|---|